is...(vegasvic1)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RCHA, Announces Assignment Agreement Acquiring Complete Ownership, Development and Commercialization Rights For Indication, Patents And Intellectual Property Related To The Treatment of Hodgkin’s Lymphoma October 13, 2014 Beverly Hills, California—Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich" or the “Company") Rich, a cancer therapeutics development company announced that it has entered into an agreement with Richard L. Chang Holdings, LLC based in New Jersey for ownership to its investigational cancer patent assignment using Phorbol Esters in the treatment of Hodgkin’s Lymphoma. Hodgkin lymphoma is a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types of Hodgkin Lymphoma are classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Currently, this disease effect over 100,000 patients annually. In 2014, it is estimated that there will be 9,190 new cases of Hodgkin lymphoma and an estimated 1,180 people will die of this disease. “We anticipate this acquisition will contribute meaningfully to our overall corporate strategy in becoming a diversified pharmaceutical company focused in oncology” stated Ben Chang, Chairman and CEO of Rich Pharmaceuticals, Inc. “Obtaining ownership of this new patent is the latest effort in our active pursuit of additional long term synergistic growth opportunities for our organization.” "We are excited to expand our pipeline being developed in oncology and look forward to developing RP-323 for the treatment of Hodgkin lymphoma and Acute Myelocytic Leukemia."
$RCHA, MANYYEARSOTC, I TRUELY BELIEVE WE HAVE THE STOCK OF
2015==2016==2017 HEADING TO NASDQ.
$RCHA, NOV. 14TH .06+ W/O NEW$, RETRACE N PROGRE$$, PENDING SHIPMENT & CLINICAL TRIALS TO BEGIN NEXT 10 DAYS.
WE SHOULD C .0225 BY FRIDAY,,
NXT WEEK WE C .035+ W/O NEWS
WITH NEWS WE C .055+.
$RCHA, FOR NEW PEOPLE 2 READ,,,,,,,,,,,BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China. This new batch of RP-323 represents a new second-generation compound with improved product usability and stability. Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323. Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. Mr. Chang further stated,
$RCHA, Announces Assignment Agreement Acquiring Complete Ownership, Development and Commercialization Rights For Indication, Patents And Intellectual Property Related To The Treatment of Hodgkin’s Lymphoma October 13, 2014 Beverly Hills, California—Rich Pharmaceuticals, Inc. (OTCQB: RCHA) ("Rich" or the “Company") Rich, a cancer therapeutics development company announced that it has entered into an agreement with Richard L. Chang Holdings, LLC based in New Jersey for ownership to its investigational cancer patent assignment using Phorbol Esters in the treatment of Hodgkin’s Lymphoma. Hodgkin lymphoma is a cancer of the immune system that is marked by the presence of a type of cell called the Reed-Sternberg cell. The two major types of Hodgkin Lymphoma are classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. Currently, this disease effect over 100,000 patients annually. In 2014, it is estimated that there will be 9,190 new cases of Hodgkin lymphoma and an estimated 1,180 people will die of this disease. “We anticipate this acquisition will contribute meaningfully to our overall corporate strategy in becoming a diversified pharmaceutical company focused in oncology” stated Ben Chang, Chairman and CEO of Rich Pharmaceuticals, Inc. “Obtaining ownership of this new patent is the latest effort in our active pursuit of additional long term synergistic growth opportunities for our organization.” "We are excited to expand our pipeline being developed in oncology and look forward to developing RP-323 for the treatment of Hodgkin lymphoma and Acute Myelocytic Leukemia."
RCHA NOV. HI .08 WITHOUT FDA APPROVAL RETRACE COMING.
$RCHA TREES BEEN SHAKN/SELLERS OUT/UP WE GO!!
$RCHA CEO STATED RP-23 IS in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.
PENNYPICKER WE R SOLID GOLD/TRIALS START DATE NEAR
$RCHA #7 .03 IS AN EZ TARGET BY MID NEXT WEEK,,
I AM SHOOTING 4 THE MOON HERE.
GOOD LUCK
$RCHA, a cancer therapeutics development company announced that it has entered into an investment agreement up to 4.5 Million with Macallan Partners, LLC headquartered in White Plains, NY. The investment commences under the Macallan Partners, LLC Agreement filed under Form S-1 and recently was declared effective by the Securities and Exchange Commission.
“We look forward to working with Macallan and moving forward with the clinical development of RP-323 in Acute Myelocytic Leukemia” stated Ben Chang, Chairman and CEO of Rich Pharmaceuticals, Inc.
Michael Budinich, Private equity analyst at Macallan Partners, who has over 20 years of industry experience in investment banking, market making and private equity sees “tremendous potential in the Rich investment and Macallan is looking forward to a productive relationship”
CASEY, WITH THE MAJOR INSTITUTIONS BACKING RCHA ,,,,,,
a hold AT LEAST TILL CLINICAL TRIAL NEWS HITS mid feb
CJTF, ANNOUNCES DIVIDEND POLICY OF .07-.176 PER SHARE,,,,,,
CORPORATE GOVERNANCE
DIVIDEND POLICY AND ESTIMATED 75% DIVIDEND PROJECTION OF
$0.09 TO $0.17 PER SHARE ANNUALLY FROM PROPERTY A –
GOLDFIELD BASIN
Thursday October 23, 2014 - Las Vegas, NV – Gold & Silver Mining of Nevada, Inc.
(PINK SHEETS: CJTF), a junior mining company in Nevada, announces corporate
governance dividend policy and a projection as to how the Goldfield Basin Part A of
company revenues would generate annual dividends ranging from $0.09 to $0.17 per
share from early production estimates.
The company has approved a 75% dividend policy to reward shareholders when in full
production.
The estimated values below are based on data collected from our ore test results and
surrounding history of adjoining claims.
Gold Grade Estimate at .15 to .25 ounces/ton .15 oz/t .25 oz/t
Gold Price est at $1250/ounce $187./ton $312.00/ton
Silver Grade Est. at 2.0 to 3.0 ounces/ton 2.0 oz/ton 3.0 oz/ton
Silver Price at $18/ounce $36.00/ton $54.00/ton
Combined Estimated Value Per Ton $233/ton $366.00/ton
Total Tons Process in Tons per Year 1,000,000 tons 1,000,000 tons
Gross Revenue Per Year $ 223,000,000 $ 366,000,000
Estimated Mining & Processing Costs (35%) (78,000,000) (78,000,000)
Allowance for Taxes (35%) (50,000,000) (100,000,000)
Net to Owners $ 95,000,000 $ 188,000,000
Co-owner (47,500,000) (94,000,000)
Projected Net Income to Company $ 47,500,000 $ 94,000,000
Projected 75% Dividends $ 35,625,000 $ 70,500,000
Dividends Per Share (Assuming 400 M Shares) $ 0.09 $ 0.176
DRUG TRIALS START AROUND FEB. 15TH HUGE NEWS IMMINENT!
$CJTF, CEO HAS 280 MIL RESTRICTED SHARES,,NOW U GOTTA KNOW THAT HE IS WILL NOT DILUTE HIS SHARES WITH OVER 4.9 MIL IN DIVIDENDS DUE HIM & PARTNERS.
YA GOTTA LUV IT.
139 MIL FLOAT ONLY..WOWZA
$CJTF, WE R JUST GETTING STARTED,,COPPER COMN.
$RCHA, A MUST READ THE OCOLOGY TRIALS SET 4 MID FEB. ARE FOR THE TERMINALLY ILL PATIENTS THAT THERE IS NO CURE FOR.
RESULTS OF TRIALS WIL BE FAST & FDA WILL FAST TRACK RC-23
SINCE IT WILL B ONLY CURE.
WITHIN 2-3 MONTHS WE COULD C AN EZ $2.00-$5.00 PER SHARE.
$RCHA, MACALLAN PARTNERS LTD, INVESTED/INVESTING HEAVILY IN
THE FUTURE OF RCHA!!!
$RCHA, CEO STATED, "We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
$RCHA BLOCKBUSTER DRUG N WORKS HERE!!
HUGE NEWS OUT,,,OTC: “CJTF” GOLD AND SILVER MINING OF NEVADA
COMMENCING PROCESSING AND PRODCUTION OF
REVEILLE STOCKPILED ORE
Tuesday February 10, 2015, Las Vegas, NV – Gold & Silver Mining of Nevada, Inc.
(PINK SHEETS: CJTF), a junior mining company in Nevada announced plans to
commence production at the stockpiled ore site at Reveille (Asset #26)
The company has completed contracts with a contractor. The contractor has
commenced processing analysis work of the stockpiled ore at Reveille (Asset #26) with
production permits to be announced soon.
The $17 million worth of above ground stockpiled ore at Reveille Asset #26 when
processed will generate the cash required to begin full permit operation once the
stockpiled ore is processed. Once the processing analysis has been completed by our
contractor, the company will issue a new cash flow projection for this operation.
$RCHA, CEO STATED YESTERDAY, "We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
$RCHA, AS THE PPS CLIMBS THE BUYS OF 500K-1MIL WILL SLOW DOWN,,
BUT THE NEW TRADERS ADDING 25K-200K ORDERS IS WHAT STABILIZES THE PPS.
GRADUALLY WE WILL CLIMB OVER NEXT 3-5 DAYS BACK TO .08+ MINIMUM...
RCHA, GETTING CLOSE 2 100 MIL TRADED, GONNA GET REAL INTERESTING LAST 2 HOURS TODAY.
MIGHT HIT .025+
$RCHA GET READY FOR A RUN @ .02.
$RCHA BLOCKBUSTER DRUG N WORKS HERE!!
$RCHA ANYONE THINKING THIS IS CLOSING DOWN DOES NOT KNOW HOW BIOTECHS WORK..
THIS IS FREAKN HUGE
CTIC N 2009 WENT FROM .05 TO $2.05 IN A FEW DAYS.
BLOCKBUSTER DRUG N WORKS HERE!!
PICKEMLO,, NO ONE WILL HOLD THIS DOWN WITH,,, MCAALAM FINANCIAL/INSIDERS/HEDGEFUNDS EVEN MM'S LOADING HERE TO .08+
$RCHA 80 MIL ALREADY TRADED WHEN WE HIT 110 MIL,,,
& WE WILL .02+
150 MIL .025+
$RCHA WAS .08+ IN NOV. WITHOUT YESTERDAYS NEWS,,
EZ 2 FIGURE THIS 1 OUT!!!!
$RCHA #1 ON ALL BOARDS, TRADERS R GETTING SMARTER,,
THIS IS THE ONLY PLACE 2 B!!!
$RCHA MACH1 GREAT POST CEO SAYS RCHA UNDERVALUED!!!
RCHA GONNA C .08+ WITHN 3-5 DAYS,,,
ONCE TRIALS START MID/LATE FEB ..20+.
GOOD LUCK
$RCHA SO UNDERVALUED HERE, WAS .08 NOV. W/O NEWS
HOW MANY PENNIES HAVE BREAKTHRU TECHNOLOGY IN THE ONCOLGY FIELD
WITH FDA APPROVAL & TRIALS STARTING MOD FEB???
NONE THAT I KNOW OF..
HUGE PLAY FOR SHAREHOLDERS
BEST PLAY OF 2015/2016 & 2017
$RCHA NEVER GONNA FIND A PINK PENNY W/CURE 4 CANCER,,
STRAIGHT TO NASDQ.
$RCHA HAVEN'T SOLD 1 SHARE BUT KEEP ADDING WOWZA
IF RCHA WAS TRADING NASDQ ON YESTERDAYS NEWS $20.+
$RCHA BEST PART WE R HALF WAY THERE, NEW TRADERS COMING
$RCHA ANOTHER 175+ MIL TRADING DAY WE C .0225+